Drug Profile

MOS 118

Alternative Names: AVE-0118; MOS-118

Latest Information Update: 16 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi-aventis
Developer Sanofi; sanofi-aventis
Class Antiarrhythmics; Small molecules
Mechanism of Action Potassium channel antagonists; Potassium channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Sleep apnoea syndrome
Discontinued Atrial fibrillation; Ventricular fibrillation

Most Recent Events

09 Jun 2025 MOS 118 is still in phase-I trials for Sleep-apnoea-syndrome in France
09 Jun 2025 Mosanna Therapeutics plans to initiate a phase II trial for Sleep apnoea syndrome
11 Apr 2023 Mosanna Therapeutics announces intention to submit IND for sleep apnoea syndrome by the end of 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com